See all press releases on News page. Saniona Investor Frequently Asked Questions (FAQs). For more information don't forget to sign up to Saniona's press releases. Trista Morrison, Chief Communications Officer. Email: investor@saniona.com. If you have any questions regarding Saniona's investor communication, feel free to contact us at any time.

2020-08-14 · Find the latest Saniona AB (SANION.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

2021-03-17 · Saniona received written feedback from the U.S. Food and Drug Administration (FDA) regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi syndrome (PWS) and HO. Saniona erhåller patent i USA för kombinationen av tesofensine och metoprolol fram till 2033. Saniona anlitar Laika Consulting för IR- och PR-tjänster och distribuerar ett första nyhetsbrev. Saniona erhåller godkännande av BfArM för att inleda klinisk fas 2a-studie med Tesomet för typ 2-diabetespatienter tillsammans med Profil i Tyskland. Senaste nyheter om - Saniona, aktieanalys, kursutveckling och rapporter. Saniona komplett bolagsfakta & börsnyheter från Analysguiden. Prenumerera här.

Saniona news

Saniona, ett ledande bioteknikföretag inom jonkanaler, About Saniona . Corporate Governance. Articles of Association of Saniona AB (publ) Reg. no. 556962-5345; Shareholder meetings; Nomination Committee; Board of Directors; Audit Committee; Remuneration Committee; Executive Management; Auditors; Corporate Governance Reports; Policies; Remuneration; Our Vision; Strategy and Business Model Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market See press release here . See press release here . PRESS RELEASE.

Saniona intends to develop and commercialize treatments for rare disease News Update: Saniona to present at three upcoming investor conferences. bit.ly/

The trial has got off to a flying start and after only a month, 40 percent of the 2020-03-26 · Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases of the central nervous system, today announced a new research collaboration with Boehringer Ingelheim in 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. 1 dag sedan · Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, since December 2020 when its shareholdings in Scandion Oncology fell below 5% Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, since December 2020 when its shareholdings in Scandion Oncology fell below 5%, Saniona has sold its remaining shares of Scandion Oncology A/S (Nasdaq First North Growth Market: SCOL) on the open market.

Saniona's partner Medix has initiated a Phase 3 trial for tesofensine in patients with obesity. This study is intended to form the basis for market approval in Mexico. The trial has got off to a flying start and after only a month, 40 percent of the

Clinical Trials Advance as Tesomet Granted FDA's Orphan Saniona, the therapy's maker, now plans to initiate a Phase 2b study of Jun 16, 2020 Saniona, after meeting with the FDA, plans to launch a Phase 2b trial Click here to subscribe to the Prader-Willi Syndrome News newsletter! Aug 10, 2020 The directed issue was led by Boston-based RA Capital Management LP. Saniona's institutional investors that participated include Israel's Mar 10, 2021 /EIN News/ -- PRESS RELEASE.

Teckningsoptionerna är föremål för sedvanliga omräkningsvillkor. Köp aktier i Saniona - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.
Genusvetare

SANIONA AB (PUBL) : News, information and stories for SANIONA AB (PUBL) | NASDAQ OMX STOCKHOLM: SANION | NASDAQ OMX STOCKHOLM 2020-02-18 · Saniona (OMX: SANION), a clinical stage biotech company focused on eating disorders and diseases of the central nervous system, CNS, today announces establishment of a new company to identify and Saniona - Health Care - Analysguiden. Prenumerera på Saniona. Om bolaget . Saniona är ett forsknings- och utvecklingsbolag fokuserat på läkemedel för sjukdomar i centrala nervsystemet, autoimmuna sjukdomar, metaboliska sjukdomar och smärtlindring. Bolaget har en omfattande portfölj av potentiella läkemedelskandidater i preklinisk eller 2021-04-12 · Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att man sedan december 2020, när aktieinnehavet i Scandion Oncology sjönk under 5 procent, har sålt den återstående delen av sitt innehav i Scandion Oncology A/S (Nasdaq First North Growth Market: SCOL) i ordinarie börshandel.

2021-04-03 · Saniona News: This is the News-site for the company Saniona on Markets Insider As Saniona is pioneering the path forward in HO, it is customary and expected that the responsibility of establishing the unmet need in a new disease area is that of the pioneering sponsor. »As part of our process of submitting for Orphan Drug Designations, we have recently conducted new analyses to verify the size of the PWS and HO patient populations. Saniona kunde idag meddela positiva topline-resultat från fas II-studien med Tesomet i den sällsynta sjukdomen hypotalamisk fetma.
Tullavgift sverige usa

blodtryck infektion i kroppen
intervjufragor saljare
lediga jobb dagab
scanner för negativ
kassasystem butik
psyk lund avd 2

Diluted earnings per share were SEK -1.75 (-2.67) Earnings per share were SEK -0.73 (-0.24) Diluted earnings per share were SEK -0.73 (-0.24) Business highlights in Q4 2020 Saniona achieved

Idag bedrivs forskning och utveckling inom läkemedel för behandling av diverse nervsjukdomar och autoimmuna sjukdom Redeye: Saniona - It’s a New Case (But Currently in Two Minds) Publicerad: 2020-09-03 (MFN) Saniona meddelar att nyttjandeperioden för teckningsoptioner av serie TO 2 inleds den 7 september 2020. Publicerad: 2020-09-03 (GlobeNewswire) Saniona announces that the exercise period of warrants of series TO 2 begins on September 7, 2020 Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market 2021-03-19 17:30 · GlobeNewswire Sanionas styrelseordförande J. Donalds deBethizy och VD Rami Levin samt andra styrelseledamöter och ledande befattningshavare förvärvar aktier i ordinarie börshandel 2020-08-10 · The new shares were issued at a subscription price of USD 2.12 per share (SEK18.50), and represents a discount of approximately 45 per cent compared to the volume weighted average price (VWAP) on 2020-08-14 · Find the latest Saniona AB (SANION.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. 1 dag sedan · Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att man sedan december 2020, när aktieinnehavet i Scandion Oncology sjönk under 5 procent, har sålt den återstående delen av sitt innehav i Scandion Oncology A/S (Nasdaq First North Growth Market: SCOL) i ordinarie börshandel.